Skip to main content
Passage BIO, Inc. logo

Passage BIO, Inc. — Investor Relations & Filings

Ticker · PASG ISIN · US7027121000 US Professional, scientific and technical activities
Filings indexed 412 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US PASG

About Passage BIO, Inc.

https://www.passagebio.com/

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.

Recent filings

Filing Released Lang Actions
10-Q - Passage BIO, Inc. (0001787297) (Filer)
Interim / Quarterly Report
2026-05-12 English
8-K - Passage BIO, Inc. (0001787297) (Filer)
Regulatory Filings
2026-04-28 English
8-K - Passage BIO, Inc. (0001787297) (Filer)
Regulatory Filings
2026-04-20 English
ARS - Passage BIO, Inc. (0001787297) (Filer)
Annual Report
2026-04-07 English
DEF 14A - Passage BIO, Inc. (0001787297) (Filer)
Proxy Solicitation & Information Statement
2026-04-07 English
4 - Passage BIO, Inc. (0001787297) (Issuer)
Director's Dealing
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.